← k3vl4r
Log inGet started →

LAB (Standard BioTools Inc) Price Forecast

AI-generated price forecast for Standard BioTools Inc (LAB) across 1-hour, 4-hour, daily and weekly horizons — updated continuously, with a public accuracy track record.

The desk streams live daily· see the schedule →

As of August 2026: K3vl4r's AI model currently reads LAB as 2/2 bullish · strong across its horizons (2 of 2 timeframes pointing up), with a last price of 0.6900. See our public, auditable track record →

📈 Daily Top Picks beating the S&P 500 since launch→✓ Public, verifiable track record Live system status💎 Get the full AI report · pay with XRP

Last price

0.6900

AI outlook

2/2 bullish · STRONG

Timeframes up

2 / 2

Share𝕏PostTelegram

LAB forecast by horizon

HorizonDirectionProjected move (end of horizon)Bullish prob.
1-hour———
4-hour~6 weeks out———
Daily~4 months out▲ Up+89.42%100%
Weekly~1.9 years out▲ Up+232.47%—

Latest LAB news

From the market-news feed the forecasts are read against.

  • Decoding LAB’s 21% crash as early-investor claims begin · ldr:coinstats.app · Aug 14
  • Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma · ldr:biopharmawatch.com · Aug 10
  • Standard BioTools Q2 EPS $(0.07) Misses $(0.03) Estimate, Sales $20.104M Miss $20.805M Estimate · Benzinga · Aug 5
  • Standard BioTools Sells Mass Cytometry Business Amid Pending Merger With Treeline Biosciences · MT Newswires · Jul 28

🔒

See the full LAB forecast

Interactive forecast chart, price targets, and Monte-Carlo confidence bands — plus the daily AI Top Picks book. Free to start, no card required.

Create a free account →

Already have one? Log in

LAB forecast — frequently asked

Will LAB go up?

K3vl4r's AI model currently reads LAB as 2/2 bullish · STRONG — 2 of 2 forecast horizons point up, so the overall read is leaning to the upside. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

What is the LAB price prediction for 2026?

K3vl4r's model projects LAB toward $0.6679 over the next ~4 months, a +0.9% move from $0.6620. Projections update continuously as new data arrives and are inherently uncertain. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

What price could LAB reach?

Over its longest horizon (~~1.9 years), the model's projected target for LAB is $0.6939 (+2.3% vs $0.6781). Confidence decreases the further out the horizon, so treat longer-range targets as one scenario, not a guarantee. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

Part of Healthcare forecasts — browse the full sector.

More AI forecasts

TNDMHALOSTTKEWTXMLTXPACSRVMDPGENPCVXSNDAHYPDACRVEOLSVCYT

Will LAB reach…?

Will LAB reach $1.00?Will LAB reach $2.00?Will LAB reach $3.00?Will LAB reach $5.00?

Or see the full LAB price prediction (2027–2040), or the forecast for today, tomorrow and this week.

Compare LAB

LAB vs TNDMLAB vs HALOLAB vs STTKLAB vs EWTXLAB vs MLTXLAB vs PACS

Curious how this is generated? Read how K3vl4r forecasts — the model, the confidence bands, and what we deliberately do not claim.

K3vl4r publishes a public, auditable track record of its Daily Top Picks — see the live results.

Forecasts are model-generated estimates for informational purposes only and are not financial advice. Markets are risky; past accuracy does not guarantee future results. See our Risk Disclosure.

StreamWatch on Kick·Watch on YouTube
k3vl4rTop PicksTrack recordChart indicatorsToday's outlookStream scheduleBiggest moversMarket heatmapForecasts by sectorAI reportsMarket videosCompareMethodologyBest AI toolsAboutFAQ◈ KVLHow KVL worksTokenomicsPricingX (Twitter)YouTube — daily showsTikTokTwitch — live forecastingDiscord community

Join the community on Discord and catch the desk stream live on Kick or YouTube. Create a free account →

Forecasts are AI-generated; written analysis is AI-assisted and human-reviewed. Informational only, not financial advice. See Terms, Risk Disclosure, Privacy · Methodology · Status.